ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patient with chronic myelogenous leukemia (CML)

Bone Marrow Transplantation

Volumn 32, Issue 4, 2003, Pages 355-361

  Zander, A R ^a   Kroger N ^a   Schleuning, M ^b   Finke, J ^c   Zabelina, T ^a   Beelen, D ^d   Schwerdtfeger, R ^e   Baurmann, H ^e   Bornhauser M ^f   Ehninger, G ^f   Fauser, A A ^g   Kiehl, M ^g   Trenschel, R ^d   Ottinger, H D ^d   Bertz, H ^c   Berger, J ^a   Kolb, H J ^b   Schaefer, U W ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g Clinic for Bone Marrow Transplantation and Hematology/Oncology   (Germany)

Author keywords

ATG; GvHD; MuD = Mismatched unrelated donor transplantation

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BUSULFAN; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; METHOTREXATE; OFLOXACIN; PENTAMIDINE; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BACTERIAL INFECTION; BASE MISPAIRING; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKOCYTE; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX RATIO; SURVIVAL RATE; VIRUS INFECTION; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; CHILD; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION CONDITIONING;

EID: 10744225772     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704157     Document Type: Article

References (41)

1. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
2. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
3. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204.
4. Beatty PG, Ash R, Hows JM, McGlave PB. The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers. Bone Marrow Transplant 1989; 4: 287-290.
5. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
6. Mackinnon S, Hows JM, Goldman JM et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol 1990; 18: 421-425.
7. McGlave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993; 81: 543-550.
8. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995; 86: 1228-1234.
9. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
10. Petersdorf EW, Hurley C, Dupont S et al. for the US NMDP. Analysis of 328 marrow transplants for the treatment of chronic myeloid leukemia from unrelated donors facilitated by the US National Marrow Donor Program (NMDP): effect of HLA-DRB1 allele disparity on clinical outcome. Blood 1996; 88 (Suppl.) 268a.
11. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of Busulfan, Hydroxyurea, Interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood, 1999; 94: 1517-1536.
12. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to Interferon-α therapy. Ann Intern Med 1995; 122: 254-261.
13. McGlave PB, Shu XQ, Wen W et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood 2000; 95: 2219-2225.
14. Young J, Papadopoulos E, Cunningham I et al. T-cell depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 1992; 79: 3380-3387.
15. Barrett A, Mavroudis D, Tisdale J et al. T-cell depleted bone marrow transplantation and delayed T-cell add-back to control acute GvHD and conserve a graft versus leukemia effect. Bone Marrow Transplant 1998; 21: 543-551.
16. Drobyski WR, Ash RC, Casper JT et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 1980-1987.
17. Zander AR, Zabelina T, Kroeger N et al. Use of five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999; 23: 889-893.
18. Kröger N, Zabelina T, Krüger W et al. Anti-thymocyte-globulin as part of the preparative regimen prevents acute and chronic graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 2001; 80: 209-215.
19. Finke J, Bertz H, Schmoor C et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti T-cell globulin. Br J Hematol 2000; 11: 303-313.
20. Petersdorf EW, Gooley TA, Anasetti C et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92: 3515-3520.
21. Betty PG, Anasetti C, Hansen JA et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81: 249-253.
22. Bodmer JG, Marsh SG, Albert ED et al. Nomenclature for factors of the HLA-system. Hum Immunol 1994; 41: 1-20.
23. Petersdorf EW, Longton GM, Anasetti C et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997; 89: 1818-1823.
24. Petersdorf EW, Longton GM, Anasetti C et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA 1996; 93: 15358-15363.
25. Petersdorf EW, Longton GM, Anasetti C et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-1613.
26. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
28. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-190.
29. Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
30. Horstmann M, Stockschläder M, Krüger W et al. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results. Ann Hematol 1995; 71: 77-81.
31. Eiermann TH, Lambrecht P, Zander AR. Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 1999; 23: 779-781.
32. Eiermann TH, Freitag S, Cortes-Dericks L et al. Jurkat cell-reactive anti-thymocyte globulin assessed ex vivo by flow cytometry persists three weeks in circulation. J Hematother Stem Cell Res 2001; 10: 385-390.
33. Genestier L, Fournel S, Flacher M et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91: 2360-2368.
34. Kröger N, Zabelina T, Krüger W et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001; 113: 1060-1071.
35. Trenschel R, Ross S, Jüsing J et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBST. Bone Marrow Transplant 2000; 25: 665-672.
36. Gratwohl A, Hermans J, Niederwieser D et al. Donor recipient sex combination influence transplant related mortality and relapse incidence following HLA-identical sibling blood and marrow transplantation for chronic myeloid leukemia. Hematol J 2001; 2: 363-370.
37. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
38. Mackinnon S, Papadopoulos E, Carabasi M et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses form graft-versus host disease. Blood 1995; 86: 1261-1268.
39. Zander AR, Zabelina T, Löliger C et al. Bone Marrow Transplantation from mismatched unrelated donors. In: Berdel WE, Jürgens H, Büchner Th, Ritter J, Kienast J, Vormoor J (eds). Transplantation in Hematology and Oncology II. Springer-Verlag: New York, 2003.
40. Remberger M, Storer B, Ringdén O, Anasetti C. Post transplant complications: Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002; 29: 391-397.
41. Hale G. Alemtuzumab in stem cell transplantation. Med Oncol 2002; 19 (Suppl.) S33-S47.